Vollebergh et al. reported that an aCGH classifier based on BRCA1-mutated breast cancer might be predictive for selective high-dose platinum-based chemotherapy, a DNA double-strand break-inducing regimen [13]. The gene discussed is BRCA1; the disease is breast carcinoma.